Seventh Sense revs up crucial trial for microneedle blood collector

Seventh Sense Biosystems says it hopes to file for U.S. and European marketing approval in the 2013 second-quarter for TAP, its point-of-care blood collection device that uses microneedles and doesn't need a vein to do its job. First, however, the Cambridge, MA-based company, which launched in 2008, must complete the registration trial for TAP now under way. If all goes well, Seventh Sense envisions having its CE mark and U.S. regulatory sign-off later this year, with a market launch in 2014. TAP draws blood with microneedles that work through the skin, a one-step process meant to be painless that can also be integrated into diagnostics. Release

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.